Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.36 USD | -2.54% | -7.50% | -18.75% |
May. 14 | Transcript : Curis, Inc. - Special Call | |
May. 14 | Curis, Inc. Announces Additional Data from Take Aim Leukemia Study | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 56.44 | 691.8 | 436.1 | 53.02 | 75.01 | 61.06 | - | - |
Enterprise Value (EV) 1 | 56.44 | 691.8 | 436.1 | 53.02 | 75.01 | 61.06 | 61.06 | 61.06 |
P/E ratio | -1.75 x | -13.4 x | -9.52 x | -0.9 x | -1.42 x | -1.68 x | -2.25 x | -2.25 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 63.8 x | 40.9 x | 5.22 x | 7.48 x | 6.95 x | 6.94 x | 5.74 x |
EV / Revenue | - | 63.8 x | 40.9 x | 5.22 x | 7.48 x | 6.95 x | 6.94 x | 5.74 x |
EV / EBITDA | - | - | -10.4 x | -1 x | - | -1.25 x | -1.11 x | -0.99 x |
EV / FCF | - | - | -11.6 x | - | -1.95 x | -1.3 x | -1.11 x | -1.02 x |
FCF Yield | - | - | -8.63% | - | -51.2% | -77% | -90.1% | -98.3% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 1,660 | 4,223 | 4,580 | 4,820 | 5,883 | 5,894 | - | - |
Reference price 2 | 34.00 | 163.8 | 95.20 | 11.00 | 12.75 | 10.36 | 10.36 | 10.36 |
Announcement Date | 3/19/20 | 3/16/21 | 2/24/22 | 3/13/23 | 2/8/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 10.84 | 10.65 | 10.16 | 10.02 | 8.783 | 8.795 | 10.63 |
EBITDA 1 | - | - | -41.91 | -52.79 | - | -49 | -55 | -61.42 |
EBIT 1 | - | -24.9 | -42.06 | -53.02 | -48.33 | -49.62 | -53.92 | -61.04 |
Operating Margin | - | -229.79% | -395.01% | -521.75% | -482.21% | -564.91% | -613.04% | -574.25% |
Earnings before Tax (EBT) 1 | - | -29.91 | -45.44 | -56.67 | -47.41 | -48.32 | -52.46 | -59.83 |
Net income 1 | -32.14 | -29.91 | -45.44 | -56.67 | -47.41 | -48.23 | -52.96 | -58.33 |
Net margin | - | -276.03% | -426.67% | -557.69% | -473.04% | -549.08% | -602.12% | -548.81% |
EPS 2 | -19.40 | -12.20 | -10.00 | -12.20 | -8.960 | -6.160 | -4.598 | -4.596 |
Free Cash Flow 1 | - | - | -37.62 | - | -38.43 | -47 | -55 | -60 |
FCF margin | - | - | -353.26% | - | -383.46% | -535.11% | -625.33% | -564.49% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/19/20 | 3/16/21 | 2/24/22 | 3/13/23 | 2/8/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 3.135 | 2.057 | 2.393 | 2.825 | 2.887 | 2.297 | 2.197 | 2.833 | 2.696 | 2.086 | 2.064 | 2.302 | 2.327 | 2.545 | 2.6 |
EBITDA 1 | -12.53 | -15.1 | -15.02 | -12.54 | -10.13 | -11.56 | -12.07 | -12.3 | - | -12.4 | -12 | -12 | -12 | -13 | -13 |
EBIT 1 | -12.57 | -15.13 | -15.06 | -12.61 | -10.22 | -11.63 | -12.14 | -12.37 | -12.2 | -12.47 | -12.61 | -12.3 | -12.34 | -12.62 | -13.25 |
Operating Margin | -400.86% | -735.68% | -629.38% | -446.23% | -354% | -506.18% | -552.48% | -436.57% | -452.49% | -597.75% | -611.22% | -534.12% | -530.54% | -495.87% | -509.62% |
Earnings before Tax (EBT) 1 | -13.62 | -16.11 | -15.94 | -13.29 | -11.33 | -11.56 | -11.96 | -12.18 | -11.71 | -11.88 | -12.51 | -11.99 | -12.04 | -12.32 | -13.16 |
Net income 1 | -13.62 | -16.11 | -15.94 | -13.29 | -11.33 | -11.56 | -11.96 | -12.18 | -11.71 | -11.88 | -12.41 | -12 | -12.03 | -12.32 | -13.16 |
Net margin | -434.45% | -783.13% | -666.11% | -470.58% | -392.41% | -503.22% | -544.42% | -429.97% | -434.42% | -569.32% | -601.58% | -521.39% | -517.06% | -484.28% | -506.15% |
EPS 2 | -3.000 | -3.600 | -3.400 | -2.800 | -2.400 | -2.400 | -2.400 | -2.130 | -2.030 | -2.050 | -1.677 | -1.500 | -1.317 | -0.7900 | -0.8900 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/24/22 | 5/5/22 | 8/4/22 | 11/9/22 | 3/13/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/8/24 | 5/7/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -37.6 | - | -38.4 | -47 | -55 | -60 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 0.68 | - | 0.42 | - | 1 | 1 | 1 |
Capex / Sales | - | 6.25% | - | 4.09% | - | 11.39% | 11.37% | 9.41% |
Announcement Date | 3/19/20 | 3/16/21 | 2/24/22 | 3/13/23 | 2/8/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.75% | 61.06M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CRIS Stock
- Financials Curis, Inc.